BE2011C030I2 - - Google Patents

Download PDF

Info

Publication number
BE2011C030I2
BE2011C030I2 BE2011C030C BE2011C030C BE2011C030I2 BE 2011C030 I2 BE2011C030 I2 BE 2011C030I2 BE 2011C030 C BE2011C030 C BE 2011C030C BE 2011C030 C BE2011C030 C BE 2011C030C BE 2011C030 I2 BE2011C030 I2 BE 2011C030I2
Authority
BE
Belgium
Application number
BE2011C030C
Other languages
French (fr)
Original Assignee
Novartis Ag
Mitsubishi Tanabe Pharma Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=32326722&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=BE2011C030(I2) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Novartis Ag, Mitsubishi Tanabe Pharma Corp filed Critical Novartis Ag
Publication of BE2011C030I2 publication Critical patent/BE2011C030I2/fr

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/13—Amines
    • A61K31/145—Amines having sulfur, e.g. thiurams (>N—C(S)—S—C(S)—N< and >N—C(S)—S—S—C(S)—N<), Sulfinylamines (—N=SO), Sulfonylamines (—N=SO2)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/13—Amines
    • A61K31/135—Amines having aromatic rings, e.g. ketamine, nortriptyline
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/13—Amines
    • A61K31/135—Amines having aromatic rings, e.g. ketamine, nortriptyline
    • A61K31/137—Arylalkylamines, e.g. amphetamine, epinephrine, salbutamol, ephedrine or methadone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/13—Amines
    • A61K31/135—Amines having aromatic rings, e.g. ketamine, nortriptyline
    • A61K31/138—Aryloxyalkylamines, e.g. propranolol, tamoxifen, phenoxybenzamine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/10—Alcohols; Phenols; Salts thereof, e.g. glycerol; Polyethylene glycols [PEG]; Poloxamers; PEG/POE alkyl ethers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/26—Carbohydrates, e.g. sugar alcohols, amino sugars, nucleic acids, mono-, di- or oligo-saccharides; Derivatives thereof, e.g. polysorbates, sorbitan fatty acid esters or glycyrrhizin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2013—Organic compounds, e.g. phospholipids, fats
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2013—Organic compounds, e.g. phospholipids, fats
    • A61K9/2018—Sugars, or sugar alcohols, e.g. lactose, mannitol; Derivatives thereof, e.g. polysorbates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
    • A61K9/2054—Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/4841—Filling excipients; Inactive ingredients
    • A61K9/4858—Organic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/4841—Filling excipients; Inactive ingredients
    • A61K9/4866—Organic macromolecular compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P41/00—Drugs used in surgical methods, e.g. surgery adjuvants for preventing adhesion or for vitreum substitution
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
BE2011C030C 2003-04-08 2011-09-08 BE2011C030I2 (ja)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US46121503P 2003-04-08 2003-04-08

Publications (1)

Publication Number Publication Date
BE2011C030I2 true BE2011C030I2 (ja) 2023-03-07

Family

ID=32326722

Family Applications (2)

Application Number Title Priority Date Filing Date
BE2004/0180A BE1015972A5 (fr) 2003-04-08 2004-04-07 Composes organiques.
BE2011C030C BE2011C030I2 (ja) 2003-04-08 2011-09-08

Family Applications Before (1)

Application Number Title Priority Date Filing Date
BE2004/0180A BE1015972A5 (fr) 2003-04-08 2004-04-07 Composes organiques.

Country Status (42)

Country Link
US (11) US20060275357A1 (ja)
EP (5) EP2316431B1 (ja)
JP (3) JP5495467B2 (ja)
KR (3) KR20050121712A (ja)
CN (2) CN101797241B (ja)
AR (3) AR043987A1 (ja)
AT (3) ATE414508T1 (ja)
AU (1) AU2004228929B2 (ja)
BE (2) BE1015972A5 (ja)
BR (1) BRPI0409250B8 (ja)
CA (2) CA2521325C (ja)
CL (2) CL2004000745A1 (ja)
CY (3) CY1110260T1 (ja)
DE (4) DE102004016947A1 (ja)
DK (2) DK2316431T3 (ja)
EC (1) ECSP056090A (ja)
ES (3) ES2320767T3 (ja)
FR (2) FR2854073B1 (ja)
GB (1) GB2400318B (ja)
GR (1) GR1005052B (ja)
HK (3) HK1071685A1 (ja)
HR (3) HRP20050886B1 (ja)
HU (2) HUE028247T2 (ja)
IL (3) IL170888A (ja)
IS (2) IS2682B (ja)
IT (1) ITMI20040682A1 (ja)
LU (1) LU91867I2 (ja)
MA (1) MA27729A1 (ja)
MX (1) MXPA05010860A (ja)
MY (1) MY141249A (ja)
NO (4) NO329332B1 (ja)
NZ (3) NZ542622A (ja)
PE (5) PE20131352A1 (ja)
PL (2) PL1613288T3 (ja)
PT (1) PT1613288E (ja)
RU (5) RU2358716C2 (ja)
SG (1) SG175449A1 (ja)
SI (2) SI1613288T1 (ja)
TN (1) TNSN05256A1 (ja)
TW (1) TWI332847B (ja)
WO (1) WO2004089341A1 (ja)
ZA (1) ZA200507394B (ja)

Families Citing this family (68)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2574664C (en) * 2004-07-30 2013-01-15 Novartis Ag Compound formulations of 2-amino-1,3-propanediol compounds
CN1891212B (zh) * 2005-07-07 2010-10-13 马启明 一种口服制剂及其制备方法
PL1926483T3 (pl) * 2005-09-09 2011-05-31 Novartis Ag Leczenie chorób autoimmunologicznych
KR101274417B1 (ko) 2005-11-09 2013-06-17 프로테올릭스, 인코퍼레이티드 효소 저해를 위한 화합물
TWI389683B (zh) * 2006-02-06 2013-03-21 Kyorin Seiyaku Kk A therapeutic agent for an inflammatory bowel disease or an inflammatory bowel disease treatment using a 2-amino-1,3-propanediol derivative as an active ingredient
CA2657213C (en) 2006-06-19 2017-01-03 Proteolix, Inc. Peptide epoxyketones for proteasome inhibition
GB0612721D0 (en) 2006-06-27 2006-08-09 Novartis Ag Organic compounds
EP1923055A1 (en) * 2006-09-26 2008-05-21 Novartis AG Freeze-dried pharmaceutical composition comprising an S1P agonist or modulator
EP1923058A1 (en) * 2006-09-26 2008-05-21 Novartis AG Coated pharmaceutical composition comprising an S1P agonist or modulator
EP1923054A1 (en) * 2006-09-26 2008-05-21 Novartis AG Fast disintegrating pharmaceutical composition comprising an S1P agonist or modulator
EP1905434A1 (en) * 2006-09-26 2008-04-02 Novartis AG Organic compounds comprising an S1P receptor agonist and their therapeutic use
AU2011235934A1 (en) * 2006-09-26 2011-11-03 Novartis Ag Pharmaceutical compositions comprising an S1P modulator
WO2008037421A2 (en) * 2006-09-26 2008-04-03 Novartis Ag Pharmaceutical compositions comprising an s1p modulator
WO2008124210A1 (en) * 2007-02-14 2008-10-16 Emory University Methods and compositions for treating or preventing infection using leukocyte sequestration agents
SG179497A1 (en) * 2007-03-29 2012-04-27 Daiichi Sankyo Co Ltd Pharmaceutical composition
MY173938A (en) 2007-10-04 2020-02-27 Onyx Therapeutics Inc Crystalline peptide epoxy ketone protease inhibitors and the synthesis of amino acid keto-epoxides
AU2012216630B2 (en) * 2007-10-12 2015-01-22 Novartis Ag Compositions comprising sphingosine 1 phosphate (S1P) receptor modulators
EP3733162A1 (en) * 2007-10-12 2020-11-04 Novartis AG Compositions comprising sphingosine 1 phosphate (s1p) receptor modulators
JP5534645B2 (ja) * 2008-01-11 2014-07-02 日医工株式会社 無包装状態において安定性に優れた塩酸サルポグレラート含有経口投与製剤
TW200946105A (en) 2008-02-07 2009-11-16 Kyorin Seiyaku Kk Therapeutic agent or preventive agent for inflammatory bowel disease containing amino alcohol derivative as active ingredient
CN104800208A (zh) 2008-03-17 2015-07-29 埃科特莱茵药品有限公司 选择性s1p1受体激动剂的给药方案
MX2010014209A (es) * 2008-06-20 2011-02-21 Merck Patent Gmbh Matriz de comprimidos de compresion directa y rapida desintegracion.
EP3011958A1 (en) 2008-06-20 2016-04-27 Novartis AG Paediatric compositions for treating multiple sclerosis
PT2334202E (pt) * 2008-09-04 2012-02-28 Cargill Inc Fabrico de comprimidos de eritritol
PE20120059A1 (es) 2008-10-21 2012-02-27 Onyx Therapeutics Inc Combinaciones farmaceuticas con epoxicetonas peptidicas
AU2009315735B2 (en) 2008-11-11 2013-01-10 Novartis Ag Salts of fingolimod
AU2013100533B4 (en) * 2008-11-11 2013-12-12 Novartis Ag Crystalline forms of fingolimod HCL
CA2743232C (en) 2008-11-11 2015-12-29 Novartis Ag Crystalline forms of fingolimod hcl
SI2371830T1 (sl) 2008-12-17 2014-01-31 Daiichi Sankyo Company, Limited Postopek za pridobivanje diaminskih derivatov
WO2010082531A1 (ja) 2009-01-13 2010-07-22 第一三共株式会社 活性化血液凝固因子阻害剤
JP5666424B2 (ja) 2009-03-10 2015-02-12 第一三共株式会社 ジアミン誘導体の製造方法
JP5652879B2 (ja) 2009-03-13 2015-01-14 第一三共株式会社 光学活性なジアミン誘導体の製造方法
TWI504598B (zh) 2009-03-20 2015-10-21 Onyx Therapeutics Inc 結晶性三肽環氧酮蛋白酶抑制劑
ES2605034T3 (es) * 2009-06-18 2017-03-10 Daiichi Sankyo Company, Limited Composición farmacéutica con solubilidad mejorada
US9675566B2 (en) 2009-07-16 2017-06-13 Pathologica Llc Method of treatment with anti-inflammatory and analgesic compounds which are GI-, renal-, and platelet-sparing
WO2011060179A1 (en) 2009-11-13 2011-05-19 Onyx Therapeutics, Inc Use of peptide epoxyketones for metastasis suppression
MA34133B1 (fr) 2010-03-01 2013-04-03 Onyx Therapeutics Inc Composes pour inhibiteurs de l'immunoproteasome
JP5390014B2 (ja) 2010-03-19 2014-01-15 第一三共株式会社 抗凝固剤の溶出改善方法
JP5692873B2 (ja) 2010-03-19 2015-04-01 第一三共株式会社 ジアミン誘導体の結晶およびその製造方法
EP2560619A2 (en) * 2010-04-22 2013-02-27 Ratiopharm GmbH A method of preparing an oral dosage form comprising fingolimod
WO2012002538A1 (ja) 2010-07-02 2012-01-05 第一三共株式会社 光学活性ジアミン誘導体の塩の製造方法
WO2012070059A1 (en) 2010-11-25 2012-05-31 Shilpa Medicare Limited Fingolimod polymorphs and their processes
PT2665471T (pt) 2011-01-19 2018-03-21 Pathologica Llc Formas de dosagem farmacêutica orais de libertação controlada que compreendem mgbg
JO3177B1 (ar) * 2011-04-01 2018-03-08 Novartis Ag تركيبات تتالف من 2-أمينو-2- [ 2- ( 4- أكتيل فينيل ) إثيل ] بروبان - 3, 1- ديول
EP2739272A1 (en) 2011-08-01 2014-06-11 Teva Pharmaceutical Industries Ltd. Process for preparing pharmaceutical compositions comprising fingolimod
US9402907B2 (en) 2011-08-10 2016-08-02 Daiichi Sankyo Company, Limited Pharmaceutical composition containing diamine derivative
WO2013091704A1 (en) 2011-12-22 2013-06-27 Synthon Bv Pharmaceutical composition comprising fingolimod
RU2482842C1 (ru) * 2012-04-26 2013-05-27 Открытое акционерное общество "Новосибхимфарм" Фармацевтическая композиция агониста рецептора s1p для лечения демиелинизационных заболеваний (варианты) и способ ее получения
RU2506949C1 (ru) * 2012-06-13 2014-02-20 Открытое акционерное общество "Новосибхимфарм" Фармацевтическая композиция агониста рецептора s1p для лечения демиелинизационных заболеваний
WO2014011695A2 (en) 2012-07-09 2014-01-16 Onyx Therapeutics, Inc. Prodrugs of peptide epoxy ketone protease inhibitors
RU2496486C1 (ru) * 2012-07-11 2013-10-27 Александр Васильевич Иващенко Фармацевтическая композиция с улучшенной сыпучестью, лекарственное средство, способ получения и применение
EP3831372A1 (en) 2013-01-08 2021-06-09 Pathologica LLC Mitoguazone for preventing the relapse or the progression of multiple sclerosis
WO2014141298A2 (en) * 2013-03-11 2014-09-18 Astron Research Limited Stable pharmaceutical composition of fingolimod
WO2014175287A1 (ja) * 2013-04-26 2014-10-30 国立大学法人 京都大学 脳動脈瘤の形成および／または増大の抑制若しくは縮小用医薬組成物
WO2013190151A1 (en) * 2013-05-13 2013-12-27 Synthon B.V. Pharmaceutical composition comprising fingolimod
JP6316422B2 (ja) * 2013-07-29 2018-04-25 アイザント ドラッグ リサーチ ソリューションズ プライベート リミテッドＡｉｚａｎｔ Ｄｒｕｇ Ｒｅｓｅａｒｃｈ Ｓｏｌｕｔｉｏｎｓ Ｐｖｔ Ｌｔｄ フィンゴリモドの医薬組成物
RU2530626C1 (ru) * 2013-10-21 2014-10-10 Ооо "Валента-Интеллект" Фармацевтическая композиция агониста рецептора s1p для лечения демиелинизационных заболеваний
WO2016026461A1 (en) * 2014-08-22 2016-02-25 Sunshine Lake Pharma Co., Ltd. Solid composition of fingolimod and preparation thereof
WO2016042493A1 (en) * 2014-09-19 2016-03-24 Aizant Drug Research Pvt. Ltd Pharmaceutical compositions of fingolimod
CA2974375A1 (en) * 2015-01-20 2016-07-28 Handa Pharmaceuticals, Llc Stable solid fingolimod dosage forms
US9925138B2 (en) 2015-01-20 2018-03-27 Handa Pharmaceuticals, Llc Stable solid fingolimod dosage forms
CA2973540A1 (en) 2015-02-26 2016-09-01 Novartis Ag Treatment of autoimmune disease in a patient receiving additionally a beta-blocker
RU2577230C1 (ru) * 2015-04-09 2016-03-10 Общество с ограниченной ответственностью "Лонг Шенг Фарма Рус" Способ получения капсул финголимода гидрохлорида
US9690975B2 (en) * 2015-05-28 2017-06-27 Axogen Corporation Quantitative structural assay of a nerve graft
WO2018178744A1 (en) 2017-03-29 2018-10-04 Deva Holding Anonim Sirketi Stable formulations of fingolimod
GR1009654B (el) 2018-08-31 2019-11-18 Φαρματεν Α.Β.Ε.Ε. Φαρμακευτικο σκευασμα που περιλαμβανει εναν ανοσοτροποποιητικο παραγοντα και μεθοδος για την παρασκευη αυτου
DE102018217334A1 (de) * 2018-10-10 2020-04-16 Harbins Ruhr Bioscience, Inc. Sphingoid-Base und/oder Wirkstoff zur Verwendung bei der Prophylaxe und/oder Therapie einer viralen Infektion und/oder viralen Infektionskrankheit oder der Desinfektion, Nahrungsmittel/Nahrungsergänzungsmittel, Futtermittel/Futterergänzungsmittel und Pflanzenschutzmittel
EP4181906A1 (en) 2020-07-16 2023-05-24 Harbins Ruhr Bioscience, Inc. Sphingoid compounds for use in prophylaxis and/or therapy of coronaviridae infection

Family Cites Families (32)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
NL7607683A (nl) * 1976-07-12 1978-01-16 Akzo Nv Werkwijze ter bereiding van nieuwe peptiden en peptide-derivaten en de toepassing hiervan.
US4110332A (en) * 1977-05-05 1978-08-29 Chevron Research Company 1-Triorganostannyl-3-organothio-4-substituted-1,2,4-delta2 -triazolidin-5-ones
US4559153A (en) 1983-10-25 1985-12-17 Phillips Petroleum Company Metal working lubricant
US5112616A (en) * 1988-11-30 1992-05-12 Schering Corporation Fast dissolving buccal tablet
JP2841857B2 (ja) * 1990-11-29 1998-12-24 田辺製薬株式会社 長期間安定な経口用医薬製剤
WO1994008943A1 (en) 1992-10-21 1994-04-28 Yoshitomi Pharmaceutical Industries, Ltd. 2-amino-1,3-propanediol compound and immunosuppressant
EP0778263B1 (en) 1994-08-22 2002-01-09 Welfide Corporation Benzene compound and medicinal use thereof
IL121625A (en) 1995-12-28 2001-09-13 Welfide Corp Preparation containing 2 - amino - 2 - (-2 (-4-octylphenyl) ethyl) propane - 1, 3, - dial for local topical use
US6476004B1 (en) * 1996-07-18 2002-11-05 Mitsubishi Pharma Corporation Pharmaceutical composition
JP2002241272A (ja) 1996-07-18 2002-08-28 Mitsubishi Pharma Corp 医薬処方組成物
JPH11209277A (ja) * 1998-01-19 1999-08-03 Yoshitomi Pharmaceut Ind Ltd 医薬組成物
GB9624038D0 (en) 1996-11-19 1997-01-08 Sandoz Ltd Organic compounds
EP2030614A1 (en) * 1997-02-27 2009-03-04 Novartis AG Pharmaceutical Composition comprising 2-amino-2-[2-(4-octylphenyl)ethyl]propane-1,3-diol and a lecithin
PT1319651E (pt) * 1997-04-04 2005-09-30 Mitsubishi Pharma Corp Composto 2-aminopropano-1,3-diol, sua utilizacao farmaceutica e seus intermediarios sinteticos
JPH1180026A (ja) * 1997-09-02 1999-03-23 Yoshitomi Pharmaceut Ind Ltd 新規免疫抑制剤、その使用方法およびその同定方法
JP3545595B2 (ja) 1998-04-01 2004-07-21 花王株式会社 スフィンゴ糖脂質の製造法
JP4627356B2 (ja) 1999-06-30 2011-02-09 松森　　昭 ウイルス性心筋炎の予防または治療薬剤
WO2001003739A1 (fr) * 1999-07-12 2001-01-18 Ono Pharmaceutical Co., Ltd. Inhibiteurs de fibrose contenant comme ingredient actif l'agoniste du recepteur de sphingosine-1-phosphate ou la sphingosine-1-phosphate
CN1267429C (zh) 2000-07-13 2006-08-02 三共株式会社 氨基醇衍生物
AU8533101A (en) * 2000-08-31 2002-03-13 Merck & Co Inc Phosphate derivatives as immunoregulatory agents
US6953332B1 (en) 2000-11-28 2005-10-11 St. Jude Medical, Inc. Mandrel for use in forming valved prostheses having polymer leaflets by dip coating
SK11942003A3 (sk) 2001-03-26 2004-03-02 Novartis Ag Deriváty 2-aminopropanolu, ich použitie a farmaceutická kompozícia, ktorá ich obsahuje
US7521192B2 (en) * 2001-04-18 2009-04-21 Rigel Pharmaceuticals, Inc. EDG: modulators of lymphocyte activation and migration
JP2002316985A (ja) 2001-04-20 2002-10-31 Sankyo Co Ltd ベンゾチオフェン誘導体
WO2003020313A1 (fr) 2001-09-04 2003-03-13 Ono Pharmaceutical Co., Ltd. Medicaments contre les maladies respiratoires renfermant un agent de regulation du recepteur de la sphingosine-1-phosphate
CA2461212C (en) 2001-09-27 2010-08-17 Kyorin Pharmaceutical Co., Ltd. Diaryl sulfide derivatives, salts thereof and immunosuppressive agents using the same
WO2003029184A1 (fr) 2001-09-27 2003-04-10 Kyorin Pharmaceutical Co., Ltd. Derive d'ether de diaryle, son sel d'addition et son immunosuppresseur
DE60329073D1 (de) 2002-01-18 2009-10-15 Merck & Co Inc Edg-rezeptoragonisten
CA2472713C (en) 2002-01-18 2011-07-19 Merck & Co., Inc. N-(benzyl)aminoalkylcarboxylates, phosphinates, phosphonates and tetrazoles as edg receptor agonists
AU2003214873A1 (en) 2002-01-18 2003-09-02 Ceretek Llc Methods of treating conditions associated with an edg receptor
WO2003061567A2 (en) 2002-01-18 2003-07-31 Merck & Co., Inc. Selective s1p1/edg1 receptor agonists
DK1772145T3 (da) * 2004-07-16 2011-05-30 Kyorin Seiyaku Kk Fremgangsmåde til effektiv anvendelse af medicin og fremgangsmåde til forebyggelse af bivirkninger

Also Published As

Publication number Publication date
IL197578A0 (en) 2011-07-31
NO329332B1 (no) 2010-09-27
NZ592339A (en) 2012-09-28
NZ542622A (en) 2009-01-31
AR043987A1 (es) 2005-08-17
DK1613288T3 (da) 2009-03-23
IE20040246A1 (en) 2004-12-15
DK2316431T3 (en) 2016-01-11
MA27729A1 (fr) 2006-01-02
AR078781A2 (es) 2011-11-30
US20140011885A1 (en) 2014-01-09
HRP20050886B1 (en) 2011-01-31
RU2005134173A (ru) 2006-09-10
NO20055231L (no) 2006-01-09
PL2316431T3 (pl) 2016-09-30
PE20130200A1 (es) 2013-03-09
IL242037A0 (en) 2015-11-30
PE20150676A1 (es) 2015-05-17
EP2008650A2 (en) 2008-12-31
BRPI0409250B1 (pt) 2017-07-11
JP2004307506A (ja) 2004-11-04
AU2004228929B2 (en) 2008-02-07
MY141249A (en) 2010-03-31
MXPA05010860A (es) 2006-05-25
KR20050121712A (ko) 2005-12-27
CY1117071T1 (el) 2017-04-05
GR20040100121A (el) 2004-12-17
HRP20100601A2 (hr) 2011-03-31
CY2011013I1 (el) 2014-04-09
EP1613288A1 (en) 2006-01-11
TW200503784A (en) 2005-02-01
GB2400318A (en) 2004-10-13
CA2521325A1 (en) 2004-10-21
US20110105620A1 (en) 2011-05-05
BE1015972A5 (fr) 2005-12-06
CL2011000450A1 (es) 2011-11-25
HK1155647A1 (en) 2012-05-25
EP2319502A1 (en) 2011-05-11
IS8885A (is) 2010-02-25
US20190175527A1 (en) 2019-06-13
EP2316431B1 (en) 2015-09-30
CA2521325C (en) 2010-09-14
NO20100250L (no) 2006-01-09
KR20110005320A (ko) 2011-01-17
US20200237690A1 (en) 2020-07-30
DE122011100047I1 (de) 2011-12-15
RU2009105403A (ru) 2010-08-27
CN1767819A (zh) 2006-05-03
TWI332847B (en) 2010-11-11
ES2228282A1 (es) 2005-04-01
RU2010146697A (ru) 2012-05-27
PE20050396A1 (es) 2005-07-05
IL170888A (en) 2010-06-16
FR2854073B1 (fr) 2008-03-14
JP2013177404A (ja) 2013-09-09
JP5495467B2 (ja) 2014-05-21
LU91867I9 (ja) 2019-01-03
JP5543298B2 (ja) 2014-07-09
GB0407819D0 (en) 2004-05-12
ZA200507394B (en) 2007-03-28
IS2682B (is) 2010-10-15
HRP20050886A2 (en) 2006-11-30
NO2011016I1 (no) 2011-09-19
US20080311188A1 (en) 2008-12-18
FR2854073A1 (fr) 2004-10-29
AT501681A1 (de) 2006-10-15
US20060275357A1 (en) 2006-12-07
FR11C0036I1 (fr) 2011-10-14
DE602004017847D1 (de) 2009-01-02
CA2707750A1 (en) 2004-10-21
RU2010147000A (ru) 2012-08-10
NO20131287L (no) 2006-01-09
ES2320767T3 (es) 2009-05-28
NZ586280A (en) 2011-12-22
HUE028247T2 (en) 2016-12-28
CL2004000745A1 (es) 2005-02-11
NO2011016I2 (no) 2012-08-27
CY2011013I2 (el) 2014-04-09
HK1071685A1 (en) 2005-07-29
SI1613288T1 (sl) 2009-04-30
ATE414508T1 (de) 2008-12-15
KR101367574B1 (ko) 2014-02-25
PL1613288T3 (pl) 2009-07-31
US20140255497A1 (en) 2014-09-11
NO20055231D0 (no) 2005-11-07
NO334116B1 (no) 2013-12-16
AT504853A2 (de) 2008-08-15
FR11C0036I2 (fr) 2023-12-29
CN1767819B (zh) 2010-07-28
LU91867I2 (fr) 2011-11-08
CY1110260T1 (el) 2014-04-09
EP1613288B1 (en) 2008-11-19
WO2004089341A1 (en) 2004-10-21
PE20090743A1 (es) 2009-07-17
AT501681B1 (de) 2012-04-15
CN101797241A (zh) 2010-08-11
RU2358716C2 (ru) 2009-06-20
RU2475236C2 (ru) 2013-02-20
US8324283B2 (en) 2012-12-04
PE20131352A1 (es) 2013-11-14
US20170290787A1 (en) 2017-10-12
RU2012148593A (ru) 2014-05-20
PT1613288E (pt) 2009-02-25
DE102004016947A1 (de) 2004-10-21
BRPI0409250A (pt) 2006-03-28
HUS1100016I1 (hu) 2016-08-29
US20090203798A1 (en) 2009-08-13
EP2008650A3 (en) 2011-04-27
CN101797241B (zh) 2013-03-27
EP2316431A1 (en) 2011-05-04
TNSN05256A1 (en) 2007-07-10
IS8114A (is) 2005-11-01
AR078782A2 (es) 2011-11-30
SI2316431T1 (sl) 2016-04-29
IL197578A (en) 2015-10-29
ITMI20040682A1 (it) 2004-07-06
ES2556947T3 (es) 2016-01-21
BRPI0409250B8 (pt) 2022-01-18
NO335120B1 (no) 2014-09-22
ES2228282B1 (es) 2006-02-16
US20130108675A1 (en) 2013-05-02
GB2400318B (en) 2005-08-10
DE202004021680U1 (de) 2010-04-22
US20220031609A1 (en) 2022-02-03
HRP20100601B1 (hr) 2016-12-02
KR20120101148A (ko) 2012-09-12
ECSP056090A (es) 2006-03-01
SG175449A1 (en) 2011-11-28
EP2769713A1 (en) 2014-08-27
GR1005052B (el) 2005-11-30
HRP20100600A2 (hr) 2011-03-31
JP2011006461A (ja) 2011-01-13
RU2475237C2 (ru) 2013-02-20
HK1091114A1 (en) 2007-01-12
AU2004228929A1 (en) 2004-10-21

Similar Documents

Publication Publication Date Title
BE2015C007I2 (ja)
BE2014C055I2 (ja)
BE2014C027I2 (ja)
BE2014C003I2 (ja)
BE2013C075I2 (ja)
BE2013C070I2 (ja)
BE2013C067I2 (ja)
BE2013C038I2 (ja)
BE2013C036I2 (ja)
BE2011C030I2 (ja)
BE2015C005I2 (ja)
BE2012C053I2 (ja)
BE2015C024I2 (ja)
AU2002316511A1 (ja)
AU2003207750A1 (ja)
AU2002327736A1 (ja)
AU2002329412A1 (ja)
AU2002331433A1 (ja)
AU2002332887A1 (ja)
AU2002333044A1 (ja)
AU2002337949A1 (ja)
AU2002339901A1 (ja)
AU2002340206A1 (ja)
AU2002348177A1 (ja)
AU2002351829A1 (ja)